A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated cmv vaccine (Towne)

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 843-846

  Adler, Stuart P ^a   Plotkin, Stanley A ^b   Gonezol, Eva ^c,d   Cadoz, Michel ^c   Meric, Claude ^e   Wang, Jian Ben ^a   Dellamonica, Pierre ^f   Best, Al M ^a   Zahradnik, John ^b   Pincus, Steve ^g   Berencsi, Klara ^c   Cox, William I ^g   Gyulai, Zsofia ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Swiftwater   (United States)

^c WISTAR INSTITUTE   (United States)

^d UNIVERSITY OF SZEGED   (Hungary)

^e Pasteur Merieux Connaught France   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g Virogenetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC; CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VACCINE PRODUCTION;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; AVIPOXVIRUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0032873526     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314951     Document Type: Article

References (15)

1. 1. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991;114:525-31.
2. 2. Balfour HH Jr, Welo PK, Sachs GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Trans Proc 1985;17:81-3.
3. 3. Plotkin SA, Huang E-S. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 1985;152:395-7.
4. 4. Plotkin SA, Starr SE, Friedman HM, Gönczöl E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989;159:860-5.
5. 5. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by a primary cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
6. 6. Baxby D, Paoletti E. Potential use of nonreplicating vectors as recombinant vaccines. Vaccine 1992;10:8-9.
7. 7. Taylor J, Trimarchi C, Weinberg R, et al. Efficacy studies on a canarypoxrabies recombinant virus. Vaccine 1991;9:190-3.
8. 8. Plotkin SA, Cadoz M, Meignier B, et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995;84:165-70.
9. 9. Gönczöl E, Berencsi K, Pincus S, et al, Preclinical evaluation of an ALVAC (canarypox) human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995;13:1080-5.
10. 10. Adler SP, McVoy M. Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for and effect resulting from strain heterogeneity. J Clin Microbiol 1986;24:870-2.
11. 11. Gönczöl E, Furlini G, Ianacone J, Plotkin SA. A rapid micro neutralization assay for cytomegalovirus. J Virol Methods 1986;14:37-41.
12. 12. Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to CMV glycoprotein B occur following both natural infection and immunization with human cytomegaloviral vaccines. J Infect Dis 1996;174:397-2.
13. 13. Starr SE, Dalton B, Garrabrant T, Paucker K, Plotkin SA. Lymphocyte blastogenesis and interferon production in adult human leukocyte cultures stimulated with CMV antigens. Infect Immun 1980;30:17-22.
14. 14. Britt WJ, Vugler L, Butfiloski EJ, et al. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079-85.
15. 15. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-46.